Floatz logo

Daraxonrasib

Pancreatic Cancer Metastatic

Revolution Medicines, Inc.Phase 3Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
81/ 100

Competitive context

329 Active assets in the Pancreatic Cancer Metastatic cohort.

Asset / SponsorPhaseRating
IMMUNOGLOBULIN G1, ANTI-(HUMANIZED MOUSE MONOCLONAL HR3 .BETA.1 CHAIN ANTI-HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR), DISULFIDE WITH HUMANIZED MOUSE MONOCLONAL HR3 .KAPPA.-CHAIN, DIMER
Chinese PLA General Hospital
Phase 4BBB
Metformin
State University of New York - Downstate Medical Center
Phase 2BBB
FLUOROURACILUM
Jonsson Comprehensive Cancer Center
Phase 4BBB
S-1
Liu Xiufeng
Phase 4BB
Eloxatin
Jonsson Comprehensive Cancer Center
Phase 4BB

View all 50 →

Same molecule, other indications

Daraxonrasib is also rated in:

pancreatic adenocarcinomaDormant
BB
Indicative ·
66 / 100
View asset →
pancreatic ductal adenocarcinomaDormant
BB
Indicative ·
66 / 100
View asset →
pancreatic adenosquamous carcinomaDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →